The value: why localisation pays off across global trials
June 26, 2026 | Localisation, clinical trials, translation
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
In our first two articles, we looked at where translation falls short and what good localisation actually looks like. Now we come to the part that affects timelines, budgets and trial delivery: the operational impact of getting localisation wrong.
Poor localisation rarely announces itself. It shows up quietly, in extra questions, slower processes, and avoidable rework. Strong localisation does the opposite. It keeps trials moving and helps sites focus on participants.
Where poor localisation creates friction
When materials don’t quite land, the effects ripple across sites and regions. Teams often see more site queries, with participants asking staff to explain content that should already be clear. Consent and onboarding slow down as confusion delays decisions. And when materials need revising market by market after launch, rework quickly builds.
These aren’t isolated problems. In our recent report The Site Factor, 27% of European respondents cited delays in receiving sponsor materials as their biggest barrier to enrolling participants. Just 24% of site teams say they use sponsor-provided materials, while others supplement them with their own materials or report having no participant-facing materials at all.
The hidden cost of fixing content late
Fixing localisation late is far more expensive than getting it right early. A single change to a master document can trigger updates across every language version, requiring fresh review, approval and redistribution. When amendments arrive out of sequence, sites are left unsure what to apply and when.
That uncertainty has a cost. It pulls site staff away from participants, adds review cycles, and risks inconsistency across regions. The later you spot the gap, the wider it spreads.
How strong localisation supports smoother delivery
Done well, localisation removes friction before it starts. Content arrives ready to use, reducing the burden on site teams to interpret, adapt or explain materials that participants find difficult to understand.
Across a trial, those benefits add up: fewer clarification queries for site staff, more consistent understanding across markets, smoother consent and onboarding processes, and less need for local workarounds or supplementary materials.
When participants understand what’s being asked of them, they’re more likely to engage and stay. And a better participant experience links directly to greater study completion.
Localisation, risk and diversity
Localisation isn’t just about clarity. It’s about reach. If your materials only work for some communities, your trial only reaches those communities. That limits diversity and skews representation, ultimately affecting the quality of the data generated.
Strong localisation helps you recruit fairly across regions and cultures. It reduces protocol misunderstandings, supports adherence, and lowers the risk of avoidable delays. In short, it makes trials more efficient and more representative.
Bringing the series together
Across these three articles, one idea has stayed constant. While translation carries the language, localisation carries the meaning.
That difference shapes how participants interpret, trust and engage with your trial. Treat localisation as a core part of your trial communication strategy, not a final production step, and you’ll see the value in smoother delivery, stronger engagement and better outcomes for everyone involved.
And that’s a goal worth building towards.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
Clarity in clinical trials
Discover how transparent, empathetic communication and health literacy principles can empower patients and enhance engagement in clinical trials, transforming participants into active partners in their healthcare journey.
Caring for patients’ mental health in clinical trials
We look at why ensuring continuous mental health support for patients in clinical trials is essential to enhance their overall well-being and trial engagement.
Driving equitable healthcare: The role of DE&I in clinical trials
Diversity, equity and inclusion (DE&I) is becoming a bigger topic of conversation and meaningful action within clinical trials. And for good reason, too. Find out why we embrace this and…
Empowering patients through more accessible clinical trial information
Senior Medical Writer, Scott Palmer explores the challenges and solutions in enhancing patient engagement in clinical trials, from the pivotal role of healthcare professionals, to the importance of user-friendly trial…
New report now available: Integrating ‘patient first’ into medicine development
A new report has just been published by Cuttsy+Cuttsy that collates all the current best thinking in the ‘patient first’ space, distilling it into a practical and actionable road map…
The digital prescription – enhancing the patient experience with technology
We explore how digital health innovations are revolutionising patient care by enhancing accessibility, personalisation, and engagement, promising a more connected and empowered patient experience.
Compliance — a driving force for influencing public perceptions of the pharma industry?
How does compliance play into public perceptions of pharma and why is it important for improving public opinion?
Another year, another B!
Louise Jones, Cuttsy+Cuttsy’s Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.
Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director
Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.
Clinical trial considerations: Why supporting HCPs matters…
When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.